LLY Price Prediction: Lilly’s earnings upgrade keeps the stock pinned below resistance

What happened and why it matters

Eli Lilly’s latest catalyst is the company’s third-quarter 2026 report on October 29, 2026. Revenue rose 39% year over year to $24.4 billion, driven primarily by Mounjaro and Zepbound, while reported EPS increased 16% to $7.22 and non-GAAP EPS rose 7% to $7.48. Management also raised the midpoint of 2026 full-year revenue guidance by $5.5 billion to a range of $91.0 billion to $92.0 billion and lifted underlying non-GAAP EPS guidance. That is the real-world backdrop for the tokenized LLY instrument: the equity story is being supported by earnings and guidance, not by technical strength alone. citeturn0search0

The analyst side has also turned more constructive. On November 2, Cantor Fitzgerald lifted its Lilly target to $1,600 from $1,440 and kept an Overweight rating, while the note cited a higher 2027 top-line revenue estimate of $109 billion versus $102.7 billion previously. Separate target updates in the last week also point higher, with Bank of America Securities at $1,557 and Leerink Partners at $1,508, according to the analyst summaries provided. citeturn0search1

Binance token price action: firm, but not decisive

On Binance Futures, LLY is trading at $1,391.03, above the 7-day, 20-day, and 50-day moving averages at $1,378.76, $1,350.02, and $1,253.62. That keeps the intermediate trend constructive. The token is also above the 12-day EMA at $1,368.54 and the 26-day EMA at $1,330.22, which reinforces the broader uptrend structure. citeturn0search2

But the trade is not cleanly one-sided. The 14-day RSI is 64.39, which sits in neutral territory rather than an overbought breakout regime, and the MACD histogram is flat at 0.0000, signaling momentum has paused even as price holds up. Daily ATR is $46.80, so swings remain wide enough that a failed breakout can travel quickly. citeturn0search2

Key levels traders are watching

The market is now leaning on the pivot at $1,379.70. Above that, immediate resistance sits at $1,406.04 and stronger resistance at $1,421.04. A sustained push through that band would bring the upper Bollinger Band at $1,464.62 back into play. On the downside, immediate support is $1,364.70, with stronger support at $1,338.36. citeturn0search2

That setup matters because the current price is already close to the upper half of the Bollinger envelope, with %B at 0.6789. In plain terms, the token is not stretched enough to force a reversal, but it is close enough to resistance that buyers still need follow-through to keep the move alive. citeturn0search2

Derivatives tape is mixed, not euphoric

The derivatives data does not confirm a crowded bullish bet. Funding is neutral at 0.0000%, open interest is 1,952.65 contracts, and open interest value is $2,528,710, with a 24-hour increase of 2.35%. That suggests participation has risen, but without an obvious directional funding skew. citeturn0search2

The directional split is softer. Binance global accounts show 47.8% long versus 52.2% short, while top-trader accounts are 45.6% long versus 54.4% short. The 1-hour taker buy/sell ratio is 0.6563, with 120 buy volume versus 183 sell volume, which points to more aggressive selling pressure in the short term. These are Binance cohorts, not a read-through on Lilly shareholders or the underlying company’s investor base. citeturn0search2

Fundamental backdrop versus tape

The underlying equity story is still anchored by earnings momentum. Lilly’s Q3 report and raised guidance provide a clear fundamental support case, and the analyst revisions supplied here are broadly aligned with that improvement. The problem for the tokenized instrument is timing: the cash-equity narrative is improving, but the Binance tape is showing resistance, neutral funding, and heavier taker-side selling. citeturn0search0turn0search1turn0search2

For now, the cleanest read is that LLY has held its trend after the earnings-driven repricing, but it still needs a decisive move through $1,406.04 and then $1,421.04 to shift from consolidation toward continuation. Failure to hold $1,379.70 would weaken that case and raise the odds of a retreat toward $1,364.70 and then $1,338.36. citeturn0search2